ArticleFrontiers in oncology2022

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial.

Yuping Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.